佳兆業集團(01638.HK)建議額外發行美元優先票據
格隆匯4月20日丨佳兆業集團(01638.HK)發佈公吿,公司建議根據原有票據的條款及條件(發行日期及發行價除外)進行優先票據的進一步國際發售據(將與2023年到期的5億美元9.75%優先票據合併並形成單一系列)。公司將就額外票據在新交所上市及報價向新交所作出申請。
公司現正提出要約,按2021年6月9日票據每1,000美元本金額作價1,001.5美元的購買價及2021年6月30日票據每1,000美元本金額作價1,001.5美元的購買價以現金購買任何及全部發行在外2021年6月9日票據及2021年6月30日票據。公司已於今日向合資格持有人提出購買要約,當中載列(其中包括)要約條款及條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.